Clinical utility and safety of MultiHance® in magnetic resonance imaging of liver cancer:: Results of multicenter studies in Europe and the USA

被引：13

作者：

Hamm, B

Kirchin, M

Pirovano, G

Spinazzi, A

机构：

[1] Bracco Ind Chim Spa, Med & Regulatory Affairs, I-20134 Milan, Italy

[2] Humboldt Univ, Dept Radiol, D-10117 Berlin, Germany

来源：

JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY | 1999年 / 23卷

关键词：

gadobenate dimeglumine; Gd-BOPTA; MR imaging; focal liver lesions;

D O I：

10.1097/00004728-199911001-00008

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

MultiHance(R) (gadobenate dimeglumine; Gd-BOPTA, Bracco SpA, Milano, Italy) is a novel gadolinium-based contrast agent which has recently been made commercially available in Europe for magnetic resonance imaging of the liver. It combines the properties of a conventional extracellular fluid contrast agent with those of a liver-specific agent and has been shown in numerous clinical trials to improve the impact of magnetic resonance imaging for both the detection and characterization of focal liver masses. The present article briefly summarizes the safety and efficacy results of Phase I, II and III clinical studies carried out in almost 800 patient and non-patient volunteers in both Europe and the USA.

引用

页码：S53 / S60

页数：8

共 26 条

[21] Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: Results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers [J].